期刊文献+

各代质子泵抑制剂在临床应用的药理变化分析 被引量:4

下载PDF
导出
摘要 目的通过对奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、依索拉唑等五代质子泵抑制剂的药理性特点进行分析,从而体现其药理变化对医学发展的促进作用。方法本文以40例溃疡性患者作为临床病例,对照组常规治疗并泮托拉唑针剂治疗,治疗组常规性治疗基础上予以依索拉唑,观察以泮托拉唑与依索拉唑为代表的两代质子泵抑制剂的临床效果。结果治疗组患者疗效明显优于对照组,且在胃内维持pH值的时间也较长,2组比较差异有统计学意义。结论质子泵抑制剂是治疗溃疡性疾病的有效药物,自其诞生之日起,就对溃疡性疾病的治疗起到了推动作用。随着医疗事业的发展与进步,其药理作用也发生了一定的变化。
作者 王婕鹏
出处 《基层医学论坛》 2013年第29期3920-3921,共2页 The Medical Forum
  • 相关文献

参考文献4

二级参考文献37

  • 1高晓红,潘伯荣.新型质子泵抑制剂-兰索拉唑[J].新消化病学杂志,1996,4(3):158-159. 被引量:25
  • 2韩英.新型抑制胃酸药物的研究现状及进展[J].华北国防医药,2006,18(4):284-286. 被引量:5
  • 3崔银珠.抗溃疡药Leminoprazole[J].国外医药合成药、生化药、制剂分册,1997,3(18):184-185.
  • 4Rehener M,Pohner HG,Schepp W.Comparison of pantoprazoleversus omeprazole in the treatment of acute duodenal ulceration amulticenter study.Aliment Pharmacol Ther,1995,9(4):411-416.
  • 5Brunner G,Harke U.Long term therapy with pantoprazole inpatients with peptic ulceration resistant to extended high doseranitidine treatment.Aliment Pharmacol Ther,1994,8(Suppl 1)∶S59-S64.
  • 6Ho KY,Kuan A,Zao F,et al.Randomized,parallel,double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric andduodenal ulcers.J Gastroenterol,2009,44(7):697.
  • 7Mossner J,Caca K.Developments in the inhibition of gastricacid secretion.Eur J Clin Invest,2005,35:469-475.
  • 8Andersson T.Pharmacokinetics,metabolism and interactions of acid pump inhibitors.Focus on omeprazole,lansoprazole and pantoprazole.Clin Pharmacokinet, 1996,31(1):9
  • 9Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol, 1996,8(Suppl.1):S21
  • 10Chang M,Tybring G,Dahl M L,et al.Interphenotype differences in disposition and effect on gastrin levels of omeprazole:Suitability of omeprazole as a probe for CYP2C19.Br J Clin Pharmacol,1995,39(5):511

共引文献67

同被引文献42

  • 1陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:32-33.
  • 2Li H, Meng L, Liu F, et al. H '/KT -ATPase inhibitors; a patent review[ Jl. Expert 0pin Ther Pat, 2013,23 (1) : 99-111.
  • 3Binnetoglu E, Akbal E, Sen H, et al. Pantoparazole-in-duced thrombocytopenia in patients with upper gastroine- testinal bleeding[ J]. Platelets, 2015,26( I ) :10-12.
  • 4Wang X, Fang J Y, Lu R, et al. A meta-analysis: com- parison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori[ J ]. Digstion, 2006,73 (2-3) :178-186.
  • 5Devault K R. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations [ J ]. Expert Rev Gastro- enterol Hepatol, 2007,1 (2) : 197-205.
  • 6American Society of Health-System Pharmacists. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998 [ J]. Am J Health Syst Pharm, 1999,56 (4) :347-379.
  • 7Frelinger AL, Lee RD, Mulford DJ, et al.A randomized,2-period, crossover design study to assess the effectsof dexlansoprazole, lansoprazole, esomeprazole,andomeprazole on the steady-state pharmacokinetics andpharmacodynamics of clopidogrel in healthy volunteers[J].Journal of the American College of Cardiology, 2012,59(14): 1304-1311.
  • 8Lawson EB, Wu JC, Baldwin ,; RM, et al.Omeprazolelimited sampling strategies to predict area under theconcentration-time curve ratios : Implications forcytochrome P450 2C19 and 3A phenotyping[J].EuropeanJournal of Clinical Pharmacology ,2012,68 ( 4 ) : 407-413.
  • 9Kees MG, Steinke T, Moritz S, et al.Omeprazole impairsthe absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers[J].TheJournal of Clinical Pharmacology: Official Journal of theAmerican College of Clinical Pharmacology, 2012,52 ( 8 ):1265-1272.
  • 10黄垣.奥美拉唑药理机制分析及其临床应用探讨[J].医药前沿,2016,6 (8): 100-101.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部